Tandem Diabetes Care (TNDM) Has Climbed To A New High On FDA Approval

Tandem Diabetes Care (TNDM) announced after the bell Thursday that it received approval fro the FDA for the t:slim X2 Insulin Pump with Basal-IQ technology.

Tandem Diabetes Care gapped open sharply higher Friday morning and is now up 4.65 at $24.96 on above average volume. The stock has been on an upward trend for the pat 3 months and has set a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT